Defilade Capital Management L.P. Invests $25.63 Million in PTC Therapeutics, Inc. $PTCT

Defilade Capital Management L.P. acquired a new stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 376,165 shares of the biopharmaceutical company’s stock, valued at approximately $25,628,000. PTC Therapeutics comprises about 3.6% of Defilade Capital Management L.P.’s portfolio, making the stock its 13th largest position. Defilade Capital Management L.P. owned 0.45% of PTC Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in PTCT. UMB Bank n.a. bought a new stake in PTC Therapeutics during the fourth quarter worth approximately $26,000. Comerica Bank raised its position in shares of PTC Therapeutics by 868.5% in the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 469 shares during the period. Salomon & Ludwin LLC acquired a new stake in shares of PTC Therapeutics in the fourth quarter worth $41,000. IFP Advisors Inc lifted its stake in shares of PTC Therapeutics by 68.1% in the third quarter. IFP Advisors Inc now owns 765 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 310 shares during the last quarter. Finally, Allworth Financial LP boosted its holdings in shares of PTC Therapeutics by 63.8% during the 4th quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 247 shares during the period.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
• Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
• Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

PTC Therapeutics Stock Performance

PTCT opened at $68.01 on Monday. PTC Therapeutics, Inc. has a 1-year low of $43.17 and a 1-year high of $90.87. The stock has a market capitalization of $5.64 billion, a price-to-earnings ratio of -117.26, a P/E/G ratio of 5.92 and a beta of 0.56. The business has a 50 day moving average of $77.57 and a 200-day moving average of $72.71.

PTC Therapeutics (NASDAQ:PTCT) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.68. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The business had revenue of $360.52 million for the quarter, compared to analyst estimates of $298.63 million. During the same quarter in the previous year, the firm posted ($0.83) earnings per share. PTC Therapeutics’s revenue was up 101.5% compared to the same quarter last year. Equities analysts predict that PTC Therapeutics, Inc. will post 0.41 EPS for the current year.

Analyst Ratings Changes

PTCT has been the topic of a number of research analyst reports. Wall Street Zen upgraded shares of PTC Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday. TD Cowen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $75.00 to $90.00 in a research report on Friday, May 8th. Morgan Stanley upped their price target on shares of PTC Therapeutics from $93.00 to $104.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings raised PTC Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Wells Fargo & Company lifted their price objective on PTC Therapeutics from $93.00 to $106.00 and gave the stock an “overweight” rating in a research note on Friday. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Insider Buying and Selling at PTC Therapeutics

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 2,464 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $90.25, for a total value of $222,376.00. Following the sale, the insider directly owned 60,299 shares in the company, valued at $5,441,984.75. This trade represents a 3.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $90.00, for a total transaction of $1,425,060.00. Following the transaction, the director owned 21,813 shares in the company, valued at approximately $1,963,170. The trade was a 42.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 198,662 shares of company stock valued at $16,347,994 in the last ninety days. Company insiders own 5.30% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC’s approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.